RATIONALE: Roflumilast is a therapeutic agent in the treatment of chronic obstructive pulmonary disease (COPD). It has antiinflammatory effects; however, it is not known whether it can affect a biologic pathway implicated in COPD pathogenesis and progression. The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD. AcPGP is produced by extracellular matrix collagen breakdown with prolyl endopeptidase and leukotriene A4 hydrolase serving as the enzymes responsible for its production and degradation, respectively. OBJECTIVES: We hypothesized that roflumilast would decrease AcPGP, halting the feed-forward cycle of inflammation. METHODS: We conducted a single-center, placebo-controlled, randomized study investigating 12 weeks of roflumilast treatment added to current therapy in moderate-to-severe COPD with chronic bronchitis. Subjects underwent sputum and blood analyses, pulmonary function testing, exercise tolerance, and quality-of-life assessment at 0, 4, and 12 weeks. MEASUREMENTS AND MAIN RESULTS:Twenty-seven patients were enrolled in the intention-to-treat analysis. Roflumilast treatment decreased sputum AcPGP by more than 50% (P < 0.01) and prolyl endopeptidase by 46% (P = 0.02), without significant improvement in leukotriene A4 hydrolase activity compared with placebo. Roflumilast also reduces other inflammatory markers. There were no significant changes in lung function, quality of life, or exercise tolerance between roflumilast- and placebo-treated groups. CONCLUSIONS:Roflumilast reduces pulmonary inflammation through decreasing prolyl endopeptidase activity and AcPGP. As expected for lower AcPGP levels, markers of neutrophilic inflammation are blunted. Inhibiting this self-propagating pathway lessens the overall inflammatory burden, which may alter the natural history of COPD, including the risk of exacerbation. Clinical trial registered with www.clinicaltrials.gov (NCT 01572948).
RCT Entities:
RATIONALE: Roflumilast is a therapeutic agent in the treatment of chronic obstructive pulmonary disease (COPD). It has antiinflammatory effects; however, it is not known whether it can affect a biologic pathway implicated in COPD pathogenesis and progression. The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD. AcPGP is produced by extracellular matrix collagen breakdown with prolyl endopeptidase and leukotriene A4 hydrolase serving as the enzymes responsible for its production and degradation, respectively. OBJECTIVES: We hypothesized that roflumilast would decrease AcPGP, halting the feed-forward cycle of inflammation. METHODS: We conducted a single-center, placebo-controlled, randomized study investigating 12 weeks of roflumilast treatment added to current therapy in moderate-to-severe COPD with chronic bronchitis. Subjects underwent sputum and blood analyses, pulmonary function testing, exercise tolerance, and quality-of-life assessment at 0, 4, and 12 weeks. MEASUREMENTS AND MAIN RESULTS: Twenty-seven patients were enrolled in the intention-to-treat analysis. Roflumilast treatment decreased sputum AcPGP by more than 50% (P < 0.01) and prolyl endopeptidase by 46% (P = 0.02), without significant improvement in leukotriene A4 hydrolase activity compared with placebo. Roflumilast also reduces other inflammatory markers. There were no significant changes in lung function, quality of life, or exercise tolerance between roflumilast- and placebo-treated groups. CONCLUSIONS: Roflumilast reduces pulmonary inflammation through decreasing prolyl endopeptidase activity and AcPGP. As expected for lower AcPGP levels, markers of neutrophilic inflammation are blunted. Inhibiting this self-propagating pathway lessens the overall inflammatory burden, which may alter the natural history of COPD, including the risk of exacerbation. Clinical trial registered with www.clinicaltrials.gov (NCT 01572948).
Authors: Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe Journal: Thorax Date: 2007-06-15 Impact factor: 9.139
Authors: Peter M A Calverley; Klaus F Rabe; Udo-Michael Goehring; Søren Kristiansen; Leonardo M Fabbri; Fernando J Martinez Journal: Lancet Date: 2009-08-29 Impact factor: 79.321
Authors: Nathaniel M Weathington; Anneke H van Houwelingen; Brett D Noerager; Patricia L Jackson; Aletta D Kraneveld; F Shawn Galin; Gert Folkerts; Frans P Nijkamp; J Edwin Blalock Journal: Nat Med Date: 2006-02-12 Impact factor: 53.440
Authors: Bartolome R Celli; Nicholas Locantore; Julie Yates; Ruth Tal-Singer; Bruce E Miller; Per Bakke; Peter Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; Annelyse Duvoix; William MacNee; Stephen Rennard; Edwin Silverman; Jørgen Vestbo; Emiel Wouters; Alvar Agustí Journal: Am J Respir Crit Care Med Date: 2012-03-15 Impact factor: 21.405
Authors: Victor Kim; Adam Davey; Alejandro P Comellas; Meilan K Han; George Washko; Carlos H Martinez; David Lynch; Jin Hwa Lee; Edwin K Silverman; James D Crapo; Barry J Make; Gerard J Criner Journal: Respir Res Date: 2014-04-27
Authors: Peter M A Calverley; Fernando J Martinez; Leonardo M Fabbri; Udo-Michael Goehring; Klaus F Rabe Journal: Int J Chron Obstruct Pulmon Dis Date: 2012-06-20
Authors: Philip O'Reilly; Patricia L Jackson; Brett Noerager; Suzanne Parker; Mark Dransfield; Amit Gaggar; J Edwin Blalock Journal: Respir Res Date: 2009-05-18
Authors: Philip J O'Reilly; Qiang Ding; Samia Akthar; Guoqiang Cai; Kristopher R Genschmer; Dhiren F Patel; Patricia L Jackson; Liliana Viera; Mojtaba Roda; Morgan L Locy; Ellen A Bernstein; Clare M Lloyd; Kenneth E Bernstein; Robert J Snelgrove; J Edwin Blalock Journal: JCI Insight Date: 2017-11-16
Authors: Dhiren F Patel; Teresa Peiró; Amelia Shoemark; Samia Akthar; Simone A Walker; Aleksander M Grabiec; Patricia L Jackson; Tracy Hussell; Amit Gaggar; Xin Xu; Jennifer L Trevor; Jindong Li; Chad Steele; Gael Tavernier; J Edwin Blalock; Robert M Niven; Lisa G Gregory; Angela Simpson; Clare M Lloyd; Robert J Snelgrove Journal: Sci Transl Med Date: 2018-08-22 Impact factor: 17.956